Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy

Central Serous Chorioretinopathy Clinical Trial

Status Recruiting

Clinical Trial Summary

The aim of the study is to determine the efficacy and safety in treating patients with chronic central serous chorioretinopathy with the drug eplerenone.

Clinical Trial Description

• The goal of the study is to examine the short-term effects and safety of eplerenone, a systemic anti-aldosterone medication, in a group of patients with central serous chorioretinopathy (CSCR).

• There is currently no standard treatment or therapy for chronic CSCR, a potentially debilitating eye disease.

• There is evidence that high blood serum corticosteroid levels can cause or worsen CSCR

• Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR

• The study's aim is to evaluate a standardized dose of eplerenone in a controlled prospective fashion for chronic CSCR.

• The study consists of taking a standard dose of eplerenone, 25mg once daily for a week, followed by 50mg once daily, for a total of 3 months

• Patients will be monitored for efficacy and side effects from the beginning of treatment and for 6 months ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy

• NCT number: NCT02153125
• Study type: Interventional
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Michaella Goldstein, MD
• Phone: 97236974361
• Email: michgold@netvision.net.il
• Status: Recruiting
• Phase: Phase 2
• Start date: April 2014